AN2 Therapeutics, Inc.
US ˙ NasdaqGS ˙ US0373261058

Introduction

This page provides a comprehensive analysis of the known insider trading history of Charles Morgan JR Kendrick. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Charles Morgan JR Kendrick has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ANTX / AN2 Therapeutics, Inc. EVP & President, Commercial 10,116
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Charles Morgan JR Kendrick. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ANTX / AN2 Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ANTX / AN2 Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANTX / AN2 Therapeutics, Inc. Insider Trades
Insider Sales ANTX / AN2 Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ANTX / AN2 Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-03-05 ELV Kendrick Charles Morgan JR 3,504 396.3000 3,504 396.3000 1,388,635 149 1.0600 -1,384,921 -99.73
2024-10-18 ELV Kendrick Charles Morgan JR 7,417 432.1400 7,417 432.1400 3,205,182
2024-03-08 ELV Kendrick Charles Morgan JR 2,432 500.4600 2,432 500.4600 1,217,119
2023-03-09 ELV Kendrick Charles Morgan JR 2,314 462.2200 2,314 462.2200 1,069,577
2022-06-09 ANTM Kendrick Charles Morgan JR 2,200 487.4500 2,200 487.4500 1,072,390
2022-06-09 ANTM Kendrick Charles Morgan JR 2,616 488.6400 2,616 488.6400 1,278,282
2022-06-09 ANTM Kendrick Charles Morgan JR 784 489.4900 784 489.4900 383,760
2022-06-09 ANTM Kendrick Charles Morgan JR 522 490.8300 522 490.8300 256,213
2022-06-09 ANTM Kendrick Charles Morgan JR 206 491.3900 206 491.3900 101,226

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANTX / AN2 Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Charles Morgan JR Kendrick as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-05 2025-03-05 4 ELV Elevance Health, Inc.
Common Stock
S - Sale -3,504 10,116 -25.73 396.30 -1,388,635 4,008,971
2025-03-05 2025-03-03 4 ELV Elevance Health, Inc.
Common Stock
A - Award 3,686 13,620 37.10
2025-03-05 2025-03-03 4 ELV Elevance Health, Inc.
Common Stock
A - Award 2,845 9,934 40.13
2025-03-05 2025-03-03 4 ELV Elevance Health, Inc.
Common Stock
F - Taxes -2,221 7,089 -23.86 395.50 -878,406 2,803,700
2024-11-05 2024-11-01 4 ELV Elevance Health, Inc.
Common Stock
A - Award 1,710 9,287 22.57
2024-11-05 2024-11-01 4 ELV Elevance Health, Inc.
Common Stock
F - Taxes -846 7,577 -10.04 414.01 -350,252 3,136,954
2024-10-18 2024-10-18 4 ELV Elevance Health, Inc.
Common Stock
S - Sale -7,417 8,423 -46.82 432.14 -3,205,182 3,639,915
2024-03-12 2024-03-08 4 ELV Elevance Health, Inc.
Common Stock
S - Sale -2,432 15,840 -13.31 500.46 -1,217,119 7,927,286
2024-03-05 2024-03-01 4 ELV Elevance Health, Inc.
Common Stock
A - Award 2,354 18,272 14.79
2024-03-05 2024-03-01 4 ELV Elevance Health, Inc.
Common Stock
A - Award 2,154 15,918 15.65
2024-03-05 2024-03-01 4 ELV Elevance Health, Inc.
Common Stock
F - Taxes -1,484 13,764 -9.73 499.11 -740,679 6,869,750
2023-11-03 2023-11-01 4 ELV Elevance Health, Inc.
Common Stock
F - Taxes -79 15,248 -0.52 446.66 -35,286 6,810,672
2023-03-13 2023-03-09 4 ELV Elevance Health, Inc.
Common Stock
S - Sale -2,314 15,327 -13.12 462.22 -1,069,577 7,084,446
2023-03-03 2023-03-02 4 ELV Elevance Health, Inc.
Common Stock
F - Taxes -1,084 17,641 -5.79 468.78 -508,158 8,269,748
2023-03-03 2023-03-01 4 ELV Elevance Health, Inc.
Common Stock
A - Award 2,542 18,725 15.71
2023-03-03 2023-03-01 4 ELV Elevance Health, Inc.
Common Stock
A - Award 2,026 16,183 14.31
2023-03-03 2023-03-01 4 ELV Elevance Health, Inc.
Common Stock
F - Taxes -293 14,157 -2.03 469.03 -137,426 6,640,058
2022-11-03 2022-11-01 4 ELV Elevance Health, Inc.
Common Stock
F - Taxes -79 14,450 -0.54 544.53 -43,018 7,868,458
2022-06-13 2022-06-09 4 ANTM Anthem, Inc.
Common Stock
S - Sale -206 14,529 -1.40 491.39 -101,226 7,139,405
2022-06-13 2022-06-09 4 ANTM Anthem, Inc.
Common Stock
S - Sale -522 14,735 -3.42 490.83 -256,213 7,232,380
2022-06-13 2022-06-09 4 ANTM Anthem, Inc.
Common Stock
S - Sale -784 15,257 -4.89 489.49 -383,760 7,468,149
2022-06-13 2022-06-09 4 ANTM Anthem, Inc.
Common Stock
S - Sale -2,616 16,041 -14.02 488.64 -1,278,282 7,838,274
2022-06-13 2022-06-09 4 ANTM Anthem, Inc.
Common Stock
S - Sale -2,200 18,657 -10.55 487.45 -1,072,390 9,094,355
2022-06-13 2022-06-09 4 ANTM Anthem, Inc.
Common Stock
M - Exercise 987 20,857 4.97 311.48 307,431 6,496,538
2022-06-13 2022-06-09 4 ANTM Anthem, Inc.
Common Stock
M - Exercise 568 19,870 2.94 232.04 131,799 4,610,635
2022-06-13 2022-06-09 4 ANTM Anthem, Inc.
Common Stock
M - Exercise 2,774 19,302 16.78 271.27 752,503 5,236,054
2022-06-13 2022-06-09 4 ANTM Anthem, Inc.
Common Stock
M - Exercise 1,999 16,528 13.76 307.68 615,052 5,085,335
2022-03-03 2022-03-02 4 ANTM Anthem, Inc.
Common Stock
F - Taxes -110 14,529 -0.75 463.49 -50,984 6,734,046
2022-03-03 2022-03-01 4 ANTM Anthem, Inc.
Employee Stock Option (Right to Buy)
A - Award 7,729 7,729
2022-03-03 2022-03-01 4 ANTM Anthem, Inc.
Common Stock
A - Award 2,031 14,639 16.11
2022-03-03 2022-03-01 4 ANTM Anthem, Inc.
Common Stock
A - Award 1,938 12,608 18.16
2022-03-03 2022-03-01 4 ANTM Anthem, Inc.
Common Stock
F - Taxes -804 10,670 -7.01 451.50 -363,006 4,817,505
2021-11-03 2021-11-01 4 ANTM Anthem, Inc.
Employee Stock Option (Right to Buy)
A - Award 2,152 2,152
2021-11-03 2021-11-01 4 ANTM Anthem, Inc.
Common Stock
A - Award 525 11,474 4.79
2021-10-15 3 ANTM Anthem, Inc.
Common Stock
10,949
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)